Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive setting

IntroductionImmune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer, but preclinical testing of hypotheses such as combination therapies has been complicated, in part due to species incompatibility issues. For example, one of few known permissive animal models for oncolytic a...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	James H. A. Clubb, Tatiana V. Kudling, Mykhailo Girych, Lyna Haybout, Santeri Pakola, Firas Hamdan, Víctor Cervera-Carrascon, Annabrita Hemmes, Susanna Grönberg-Vähä-Koskela, João Manuel Santos, Dafne C. A. Quixabeira, Saru Basnet, Camilla Heiniö, Victor Arias, Elise Jirovec, Shreyas Kaptan, Riikka Havunen, Suvi Sorsa, Abdullah Erikat, Joel Schwartz, Marjukka Anttila, Katri Aro, Tapani Viitala, Ilpo Vattulainen, Vincenzo Cerullo, Anna Kanerva, Akseli Hemminki
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Frontiers Media S.A. 2023-02-01
Ráidu:	Frontiers in Immunology
Fáttát:	adenovirus oncolytic virus immune checkpoint inhibitor immunotherapy Syrian hamster PDAC
Liŋkkat:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1060540/full
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!